April 30, 2025Journal of the American College of Cardiology
2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease
Why the study?
Chronic coronary disease is the leading cause of death in the United States, creating an ongoing imperative to disseminate recommendations that align patient management to updated evidence-based guidelines.
Key Points
- The aim is to disseminate evidence-based and patient-centered care recommendations for chronic coronary disease.
- Developed a comprehensive measure set of 10 performance measures and 3 quality measures.
- Focused on practical steps for managing chronic coronary disease.
- Included assessments for tobacco use, antiplatelet therapy, lipid goals, hypertension management, and cardiac rehabilitation.
- Emphasized the importance of tobacco cessation interventions and patient education.
- Promoted guideline-directed management and therapy for hypertension and left ventricular dysfunction.
- Highlighted referral to cardiac rehabilitation to improve patient outcomes.
Structured PICO
P
Population
Patients with chronic coronary disease (CCD)
I
Intervention
A comprehensive CCD measure set comprising 10 performance measures and 3 quality measures (including tobacco cessation, antiplatelet therapy, lipid assessment, hypertension management, reduced LVEF management, and cardiac rehabilitation referral)
The AHA/ACC developed a new set of 10 performance and 3 quality measures to optimize evidence-based care for patients with chronic coronary disease.
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“For patients with chronic coronary disease, the landscape is changing as we advance care. The document is meant to help spread the word and really allow [clinicians] to know how we should we be managing our patients now. It can be intimidating to say, well, this changes and that changes and this changes” without knowing what to prioritize amid all the various sources of information.”
“There's more and more evidence to suggest that P2Y12 inhibitors are equivalent and certainly not inferior to aspirin therapy in patients with chronic coronary disease. That is not what we should be doing in patients who are stable, no change in their ejection fraction, no change in symptoms. This unnecessary testing doesn't benefit patients and, in some cases, can result in complications.”
Implication
Encourages adoption of updated CCD measures in practice; extends guidelines to standardize care and guide future quality research.
Abstract
Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD to updated evidence-based guidelines. The writing committee developed a comprehensive CCD measure set comprising 10 performance measures and 3 quality measures, the focus of which is to include practical steps to specifically advance care in the CCD population. The measure set begins with an assessment of tobacco use and evidence-based cessation interventions. Also included are topics such as antiplatelet therapy, lipid assessment and low-density lipoprotein cholesterol goals, and guideline-directed management and therapy for hypertension and reduced left ventricular dysfunction in patients with CCD. The measure set concludes with an emphasis on the importance of cardiac rehabilitation referral and patient education, including symptom management and lifestyle modification.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Williams et al. (2025) studied Chronic coronary disease. Clinical Performance and Quality Measures was evaluated. A comprehensive measure set comprising 10 performance measures and 3 quality measures was developed to advance evidence-based care for patients with chronic coronary disease.